M. Woodward

Cardiology and Cardiovascular Medicine · 2000–2021

A researcher in the Science corpus: 45 papers; trusts 10 researchers and is trusted by 12 researchers here, as inferred from the citation graph.

Subfields

Whom M. Woodward trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Julian P. T. Higgins
  2. S. Larsson
  3. Peter W. F. Wilson
  4. R. Huxley
  5. A. Levey
  6. Michael J. Pencina
  7. S. Thompson
  8. Esteban Walker
  9. A. Wolk
  10. Ralph B. D’Agostino

Who trusts M. Woodward overall

  1. T. Ivanova
  2. S. Peters
  3. R. Huxley
  4. R. Payne
  5. Gary S. Collins
  6. Massimo F. Piepoli
  7. A. Gary
  8. Karel G. M. Moons
  9. Johannes B Reitsma

Papers from M. Woodward's perspective

Ordered by how strongly the researchers M. Woodward trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. (Diabetes Care)
  2. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers (Statistics in Medicine)
  3. Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate (Annals of Internal Medicine)
  4. Evaluation of the Performance of Survival Analysis Models: Discrimination and Calibration Measures (Advances in Survival Analysis)
  5. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. (Kidney International)
  6. Age affects outcomes in chronic kidney disease. (Journal of the American Society of Nephrology)
  7. Regression Modeling Strategies (Technometrics)
  8. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond (Statistics in Medicine)
  9. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses
  10. Value of assessment of pretest probability of deep-vein thrombosis in clinical management.

Their papers